PT19 Emerging Trends in the Adoption of Alternative Financing Models for Advanced Therapy Medicinal Products: A Scoping Review

PT20 Impact of Huge-Seller Repricing on Price Trend for Reimbursable Cancer Drugs in Japan

PT21 Promoting Access to Innovative Drugs: A Review of National Drug Price Negotiation in China

PT22 Evaluating Reimbursement Pathway of Digital Health Technologies (DHT) Across Five European Countries

PT23 The Evolving German DiGA Market: Insights From a Claims Data Analysis

PT24 From French Early Access to Reimbursement: A Comparison of Early Access Prices and List Prices